148 related articles for article (PubMed ID: 29940414)
1. Activating Transcription Factor 3 as a Novel Regulator of Chemotherapy Response in Breast Cancer.
Hasim MS; Nessim C; Villeneuve PJ; Vanderhyden BC; Dimitroulakos J
Transl Oncol; 2018 Aug; 11(4):988-998. PubMed ID: 29940414
[TBL] [Abstract][Full Text] [Related]
2. Induction of Activating Transcription Factor 3 Is Associated with Cisplatin Responsiveness in Non-Small Cell Lung Carcinoma Cells.
Bar J; Hasim MS; Baghai T; Niknejad N; Perkins TJ; Stewart DJ; Sekhon HS; Villeneuve PJ; Dimitroulakos J
Neoplasia; 2016 Sep; 18(9):525-35. PubMed ID: 27659012
[TBL] [Abstract][Full Text] [Related]
3. Lovastatin-induced apoptosis is mediated by activating transcription factor 3 and enhanced in combination with salubrinal.
Niknejad N; Gorn-Hondermann I; Ma L; Zahr S; Johnson-Obeseki S; Corsten M; Dimitroulakos J
Int J Cancer; 2014 Jan; 134(2):268-79. PubMed ID: 23824972
[TBL] [Abstract][Full Text] [Related]
4. Activating Transcription Factor 3 regulates in part the enhanced tumour cell cytotoxicity of the histone deacetylase inhibitor M344 and cisplatin in combination.
St Germain C; O'Brien A; Dimitroulakos J
Cancer Cell Int; 2010 Sep; 10():32. PubMed ID: 20828393
[TBL] [Abstract][Full Text] [Related]
5. Doxorubicin induces cytotoxicity through upregulation of pERK-dependent ATF3.
Park EJ; Kwon HK; Choi YM; Shin HJ; Choi S
PLoS One; 2012; 7(9):e44990. PubMed ID: 23028726
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of cisplatin cytotoxicity by disulfiram involves activating transcription factor 3.
O'Brien A; Barber JE; Reid S; Niknejad N; Dimitroulakos J
Anticancer Res; 2012 Jul; 32(7):2679-88. PubMed ID: 22753726
[TBL] [Abstract][Full Text] [Related]
7. ATF3 inhibits doxorubicin-induced apoptosis in cardiac myocytes: a novel cardioprotective role of ATF3.
Nobori K; Ito H; Tamamori-Adachi M; Adachi S; Ono Y; Kawauchi J; Kitajima S; Marumo F; Isobe M
J Mol Cell Cardiol; 2002 Oct; 34(10):1387-97. PubMed ID: 12392999
[TBL] [Abstract][Full Text] [Related]
8. Increasing intratumor C/EBP-β LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer.
Salaroglio IC; Gazzano E; Abdullrahman A; Mungo E; Castella B; Abd-Elrahman GEFA; Massaia M; Donadelli M; Rubinstein M; Riganti C; Kopecka J
J Exp Clin Cancer Res; 2018 Nov; 37(1):286. PubMed ID: 30482226
[TBL] [Abstract][Full Text] [Related]
9. Inorganic Phosphate Prevents Erk1/2 and Stat3 Activation and Improves Sensitivity to Doxorubicin of MDA-MB-231 Breast Cancer Cells.
Sapio L; Sorvillo L; Illiano M; Chiosi E; Spina A; Naviglio S
Molecules; 2015 Sep; 20(9):15910-28. PubMed ID: 26340617
[TBL] [Abstract][Full Text] [Related]
10. Induction of ATF3 by ionizing radiation is mediated via a signaling pathway that includes ATM, Nibrin1, stress-induced MAPkinases and ATF-2.
Kool J; Hamdi M; Cornelissen-Steijger P; van der Eb AJ; Terleth C; van Dam H
Oncogene; 2003 Jul; 22(27):4235-42. PubMed ID: 12833146
[TBL] [Abstract][Full Text] [Related]
11. Key role of ATF3 in p53-dependent DR5 induction upon DNA damage of human colon cancer cells.
Taketani K; Kawauchi J; Tanaka-Okamoto M; Ishizaki H; Tanaka Y; Sakai T; Miyoshi J; Maehara Y; Kitajima S
Oncogene; 2012 Apr; 31(17):2210-21. PubMed ID: 21927023
[TBL] [Abstract][Full Text] [Related]
12. Activation of Akt characterizes estrogen receptor positive human breast cancers which respond to anthracyclines.
Yndestad S; Austreid E; Svanberg IR; Knappskog S; Lønning PE; Eikesdal HP
Oncotarget; 2017 Jun; 8(25):41227-41241. PubMed ID: 28476032
[TBL] [Abstract][Full Text] [Related]
13. A novel group of genes regulates susceptibility to antineoplastic drugs in highly tumorigenic breast cancer cells.
Mallory JC; Crudden G; Oliva A; Saunders C; Stromberg A; Craven RJ
Mol Pharmacol; 2005 Dec; 68(6):1747-56. PubMed ID: 16150928
[TBL] [Abstract][Full Text] [Related]
14. Second-generation proteasome inhibitor carfilzomib enhances doxorubicin-induced cytotoxicity and apoptosis in breast cancer cells.
Shi Y; Yu Y; Wang Z; Wang H; Bieerkehazhi S; Zhao Y; Suzuk L; Zhang H
Oncotarget; 2016 Nov; 7(45):73697-73710. PubMed ID: 27655642
[TBL] [Abstract][Full Text] [Related]
15. Activating Transcription Factor 3 Expression as a Marker of Response to the Histone Deacetylase Inhibitor Pracinostat.
Sooraj D; Xu D; Cain JE; Gold DP; Williams BR
Mol Cancer Ther; 2016 Jul; 15(7):1726-39. PubMed ID: 27196751
[TBL] [Abstract][Full Text] [Related]
16. Histone deacetylase (HDAC) inhibitors and doxorubicin combinations target both breast cancer stem cells and non-stem breast cancer cells simultaneously.
Hii LW; Chung FF; Soo JS; Tan BS; Mai CW; Leong CO
Breast Cancer Res Treat; 2020 Feb; 179(3):615-629. PubMed ID: 31784862
[TBL] [Abstract][Full Text] [Related]
17. PKCδ regulates death receptor 5 expression induced by PS-341 through ATF4-ATF3/CHOP axis in human lung cancer cells.
Xu L; Su L; Liu X
Mol Cancer Ther; 2012 Oct; 11(10):2174-82. PubMed ID: 22848091
[TBL] [Abstract][Full Text] [Related]
18. Src/STAT3-dependent heme oxygenase-1 induction mediates chemoresistance of breast cancer cells to doxorubicin by promoting autophagy.
Tan Q; Wang H; Hu Y; Hu M; Li X; Aodengqimuge ; Ma Y; Wei C; Song L
Cancer Sci; 2015 Aug; 106(8):1023-32. PubMed ID: 26041409
[TBL] [Abstract][Full Text] [Related]
19. Lapatinib sensitizes quiescent MDA-MB-231 breast cancer cells to doxorubicin by inhibiting the expression of multidrug resistance-associated protein-1.
Kwon YS; Chun SY; Nam KS; Kim S
Oncol Rep; 2015 Aug; 34(2):884-90. PubMed ID: 26063481
[TBL] [Abstract][Full Text] [Related]
20. Cardiac Fibroblast-Specific Activating Transcription Factor 3 Protects Against Heart Failure by Suppressing MAP2K3-p38 Signaling.
Li Y; Li Z; Zhang C; Li P; Wu Y; Wang C; Bond Lau W; Ma XL; Du J
Circulation; 2017 May; 135(21):2041-2057. PubMed ID: 28249877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
